The era of the generic bottle

For years, the word supplement was synonymous with a generic pill in an unremarkable bottle. Something your aunt recommended after noticing you looked pale at a family dinner, or that your primary doctor prescribed almost by inertia: “take a B complex and see me in a month.” And it wasn’t entirely wrong: a basic multivitamin served its purpose. The problem is that this purpose was limited, not very specific, and in many cases supported more by marketing than by evidence. For decades, the industry operated under a simple logic: if a nutrient is good, put it in a capsule and sell it. The chemical form, the real dose, and whether the body could absorb it didn’t matter much. What mattered was that the bottle said something appealing on the label.

A name for what was missing

Today the landscape is different. The term nutraceutical—coined in 1989 by Stephen DeFelice, founder of the Foundation for Innovation in Medicine—was born precisely to separate two worlds: products that simply “supplement” the diet, and those that have a demonstrable physiological effect. In other words, they not only provide nutrients but also modify body functions in a measurable and reproducible way. DeFelice proposed it with a clear vision: to create an intermediate category between food and pharmaceuticals, where science could support what nature already offered. A category that demanded standards, not just good intentions.

Same molecule, different engineering

The difference is not cosmetic. A vitamin C supplement gives you ascorbic acid, period. A nutraceutical based on liposomal vitamin C, for example, uses phospholipid encapsulation technology that improves intestinal absorption and cellular bioavailability. Same nutrient, different engineering. And that engineering changes clinical outcomes. The same applies to magnesium: it is not the same to take magnesium oxide—which has a bioavailability of less than 4% and in high doses acts more as a laxative than as a supplement—than magnesium bisglycinate, a chelated form that the intestine absorbs as a dipeptide and that also has affinity for the central nervous system. The molecule matters. How it is delivered to the body matters even more.

Three forces that changed the rules

This evolutionary leap did not happen overnight. It came from three factors that converged in the last decade. First, functional medicine began to gain ground in real clinical settings, moving from being an alternative approach to becoming a clinical model with documented protocols and reproducible results. Second, research in phytochemistry and bioavailability grew exponentially: today we have clinical studies on curcumin, silymarin, berberine, and dozens of bioactive compounds that were once considered herbal folklore. And third, the consumer changed. People stopped settling for attractive labels. They began asking how much magnesium it contains, in what chemical form, and whether there are studies supporting it. That didn’t happen ten years ago.

From trendy ingredient to therapeutic tool

Today, ingredients such as 80% standardized silymarin, N-acetylcysteine as a precursor to glutathione, curcumin as a proven anti-inflammatory, or tauroursodeoxycholic acid (TUDCA) are not passing trends or social media fads: they are therapeutic tools with mechanisms of action documented in indexed and peer-reviewed literature. And when a product is formulated with clinical criteria—with functional doses, bioactive forms, and synergy between ingredients—it stops being a supplement. It becomes a nutraceutical with purpose. It is not the same to combine five popular ingredients in a capsule as it is to design a formula where each component fulfills a specific role within a defined metabolic pathway.

The dark side of the term

Of course, this evolution also brought risks. The market has been filled with brands that use the term nutraceutical as a premium label without substance behind it. They include a trendy extract in subtherapeutic doses, add an attractive design, and sell it as cutting-edge science. We see it every day: products that claim “advanced formulas” but, upon reviewing the nutritional table, reveal quantities that do not even reach the minimum threshold to generate an effect. It is like putting a drop of coffee in a glass of milk and calling it a cappuccino. The difference between a real nutraceutical and a superficial one lies in the details: the technical sheet, extract standardization, formula transparency, identity and purity testing of the active ingredient, certificates of analysis, and above all, the criteria of the person who designed it.

The Mexican case

In Mexico, this topic has an additional nuance. COFEPRIS regulates dietary supplements under a framework that does not formally distinguish between a generic multivitamin and a hepatoprotective formula with standardized ingredients. Everything falls into the same regulatory category. The consumer sees two products on the shelf, both with sanitary registration, both legal, but with a vast difference in formulation quality. This means that the responsibility of distinguishing a serious product from an improvised one falls largely on the formulator and the healthcare professional who recommends it. We cannot expect regulation to do the work that belongs to clinical judgment. Fortunately, there are now certifications that not only guarantee safety and quality in production processes but also ensure that the formulation is well designed; such as the Global FST certification, which goes far beyond the minimum required by regulations in Mexico and other parts of the world.

Formulating with purpose

The future of supplementation is not about selling more products. It is about formulating better, with evidence, honesty, and a clinical foundation. Nutraceuticals did not come to replace pharmaceuticals or compete with conventional medicine. They came to occupy a space that always existed but was never addressed seriously: nutritional intervention with scientific rigor. A space where physicians can prescribe with confidence, where patients can make informed decisions, and where the industry has the obligation to support every ingredient with data and certifications, not promises. Those who formulate with this mindset are not selling capsules: they are building a category that public health needs.

And that space today already has a name. And those of us who build it from science, clinical practice, and formulation have the responsibility to defend it.